Community Resources

i-base – Reports from CROI 2019


HIV Treatment Bulletin, published by HIV i-base, includes early reports from the Conference on Retroviruses and Opportunistic Infections (CROI 2019).

China approves albuvirtide: a once-weekly injectable entry inhibitor


On 6 June 2018, without news from the US FDA, a press release from Frontier Biotech announced the approval of a new HIV drug in China that is given by once-weekly injection.

This is a rare example of an HIV treatment not being first approved in either the US or Europe.

Top-line phase 3 results released for cabotegravir/rilpivirine long-acting injections


On 15 August 2018, top-line results from the phase 3 ATLAS study reported that monthly injections with the dual long-acting formulation cabotegravir/rilpivirine were non-inferior as a switch option compared to remaining on triple-drug ART.

The Antiretroviral Therapy as Long Acting Suppression (ATLAS) study randomised 570 HIV positive adults who had been virally suppressed for more than six months on their first or second HIV combination.

Dual bNAb maintains viral suppression for median 21 weeks off-ART


In the first presentation in a session at R4P2018 looking at using bNAbs for prevention, Pilar Mendoza from the Rockefeller University presented results on the impact of a combination of two antibodies in HIV positive people on ART who then took an analytic treatment interruption (ATI).

Long-acting ART for children is a deferred priority despite achievable dosing


Optimal doses of long-acting injectable antiretrovirals cabotegravir and rilpivirine were predicted for different weight bands in children and adolescents.

Long-acting injectable antiretrovirals could be future alternatives to oral formulations and might help to address adherence. There is great interest in the potential use of these formulations in the treatment of paediatric HIV.